Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Halozyme Therapeutic (HALO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,271,396
  • Shares Outstanding, K 145,509
  • Annual Sales, $ 151,860 K
  • Annual Income, $ -80,330 K
  • 60-Month Beta 1.79
  • Price/Sales 15.25
  • Price/Cash Flow N/A
  • Price/Book 8.90

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.17
  • Number of Estimates 4
  • High Estimate -0.13
  • Low Estimate -0.22
  • Prior Year -0.16
  • Growth Rate Est. (year over year) -6.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.49 +0.76%
on 05/14/19
17.43 -10.44%
on 05/08/19
-0.75 (-4.58%)
since 04/17/19
3-Month
15.24 +2.43%
on 03/25/19
17.76 -12.11%
on 03/04/19
-1.43 (-8.39%)
since 02/15/19
52-Week
13.24 +17.90%
on 12/24/18
19.56 -20.19%
on 06/21/18
-2.68 (-14.65%)
since 05/17/18

Most Recent Stories

More News
Halozyme To Participate In Bank of America Merrill Lynch Health Care Conference 2019

Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will participate in the Bank of America Merrill Lynch Health Care Conference 2019...

HALO : 15.61 (-1.95%)
Halo Labs Improves Transparency with Move to OTCQX -- CFN Media

Seattle, Washington--(Newsfile Corp. - May 8, 2019) - CFN Media Group ("CFN Media"), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication...

AGEEF : 0.5400 (+6.40%)
HALO : 15.61 (-1.95%)
Halozyme Therapeutics (HALO) Matches Q1 Earnings Estimates

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 0.00% and -20.23%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

HALO : 15.61 (-1.95%)
Halozyme Therapeutics: 1Q Earnings Snapshot

SAN DIEGO (AP) _ Halozyme Therapeutics Inc. (HALO) on Tuesday reported first-quarter net income of $1.8 million, after reporting a loss in the same period a year earlier.

HALO : 15.61 (-1.95%)
Halozyme Reports First Quarter 2019 Results

Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today reported financial results for the first quarter ended March 31, 2019 and...

HALO : 15.61 (-1.95%)
Halozyme Therapeutics, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 7, 2019 / Halozyme Therapeutics, Inc. (NASDAQ: ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 7, 2019 at 4:30 PM Eastern...

HALO : 15.61 (-1.95%)
Halozyme Names Dr. Alison A. Armour As Senior Vice President Of Research And Development

Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced the appointment of biotechnology and pharmaceutical industry expert...

HALO : 15.61 (-1.95%)
Halo Expands Branded Products & Launches Hemp CBD Products -- CFN Media

Seattle, Washington--(Newsfile Corp. - April 24, 2019) - CFN Media Group ("CFN Media"), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication...

AGEEF : 0.5400 (+6.40%)
HALO : 15.61 (-1.95%)
Halozyme To Host First Quarter 2019 Financial Results Webcast And Conference Call

Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly Update Conference Call for the first quarter 2019 on...

HALO : 15.61 (-1.95%)
HALO Labs: Building A Cannabis Concentrate & Oil Empire -- CFN Media

via NEWMEDIAWIRE - CFN Media Group ("CFN Media"), the leading agency and financial media network dedicated to the North American cannabis industry announces publication of an article and on-site video...

AGEEF : 0.5400 (+6.40%)
HALO : 15.61 (-1.95%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade HALO with:

Business Summary

Halozyme Therapeutics, Inc. is a therapeutically driven, development stage biopharmaceutical company dedicated to developing and commercializing recombinant human enzymes for the infertility, ophthalmology, and oncology communities. The company's broad product development portfolio, including expected...

See More

Key Turning Points

2nd Resistance Point 16.18
1st Resistance Point 15.89
Last Price 15.61
1st Support Level 15.44
2nd Support Level 15.27

See More

52-Week High 19.56
Fibonacci 61.8% 17.15
Fibonacci 50% 16.40
Fibonacci 38.2% 15.65
Last Price 15.61
52-Week Low 13.24

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar